Rapamycin (Sirolimus) FAERS Safety Signals: What the Post-Market Data Shows

What Is the FDA Regulatory History of Sirolimus?

Sirolimus received FDA approval on September 15, 1999, under the brand name Rapamune, manufactured by Wyeth (now Pfizer). The approval covered prophylaxis of organ rejection in patients aged 13 and older receiving renal transplants. A liquid oral formulation was approved first; the 1 mg and 2 mg tablets followed in 2000. The NDA number is 21-083, accessible via the Drugs@FDA database.

Label Evolution and Black-Box Warning History

The original 1999 label did not carry a black-box warning. The FDA added the current boxed warnings progressively through post-market safety reviews. The current label warns explicitly that sirolimus is not recommended in liver or lung transplant recipients, citing increased mortality from bacterial, fungal, and viral pneumonia in lung transplant trials and an excess of hepatic artery thrombosis in liver transplant trials. The current prescribing information also warns that immunosuppression increases susceptibility to lymphoma and other malignancies, particularly of the skin.

Indication Expansion Over Time

In 2015, FDA approved sirolimus for lymphangioleiomyomatosis (LAM), a rare lung disease, based on the MILES trial. That approval, NDA 021083/S-046, extended the label to adult women with LAM. No other indications have received FDA approval, meaning all longevity and anti-aging uses remain off-label. The FDA approval letter for the LAM indication outlines post-marketing commitments Pfizer was required to fulfill.

What Does the FAERS Database Show for Sirolimus?

The FDA Adverse Event Reporting System (FAERS) is the principal pharmacovigilance tool for post-market signals in the United States. As of the most recent public data release, sirolimus has accumulated thousands of individual case safety reports since 1999. The FAERS public dashboard allows open queries by drug name and preferred term.

Top Disproportionately Reported Adverse Events

Disproportionality analysis using reporting odds ratios (ROR) and proportional reporting ratios (PRR) identifies signals where sirolimus reports exceed the background rate across all drugs in the database. Published pharmacovigilance analyses have consistently identified the following signal clusters for sirolimus:

• Pulmonary toxicity. Sirolimus-associated pneumonitis appears in FAERS at a PRR well above the threshold of concern. A 2011 analysis published in Drug Safety identified interstitial pneumonitis as one of the strongest disproportionality signals for mTOR inhibitors, with sirolimus and everolimus both generating PRR values exceeding 4.0 for ILD-related preferred terms.
• Metabolic disturbances. Hyperlipidemia and hypertriglyceridemia are among the most frequently reported adverse events in both clinical trial data and FAERS. The sirolimus label notes that 38 to 52% of patients in registration trials developed hypertriglyceridemia requiring treatment.
• Wound-healing impairment. Case reports and FAERS submissions document delayed incision healing, dehiscence, and lymphocele formation, particularly in the peri-transplant period.
• Hematologic signals. Thrombocytopenia and anemia appear with disproportionate frequency in FAERS for sirolimus relative to other immunosuppressants.
• Stomatitis and oral mucositis. This signal is class-related across mTOR inhibitors. A pooled analysis cited by the European Medicines Agency EPAR for Rapamune noted aphthous-like ulcers in 16 to 39% of transplant patients depending on the dosing regimen.

How FAERS Signal Strength Is Interpreted

A signal in FAERS does not confirm causation. The system is voluntary, subject to underreporting, and biased toward serious outcomes. The FDA uses FAERS in combination with the Sentinel System, which draws on electronic health records and insurance claims from over 500 million patient-years of data, to validate signals before regulatory action. The FDA Sentinel Initiative has been used for mTOR inhibitors in the post-2012 period, though published Sentinel modules specific to sirolimus longevity use are not yet publicly available.

What Are the Most Clinically Significant Sirolimus Safety Signals?

Sirolimus-Associated Pneumonitis (SAP)

Sirolimus-associated pneumonitis is the signal most likely to require treatment discontinuation outside of infection-related adverse events. A systematic review by Morales-Buenrostro et al. Estimated an incidence of approximately 3.6% in renal transplant recipients on sirolimus maintenance, though the true rate in off-label, low-dose contexts is unknown. The 2007 case series published in Transplantation described radiographic patterns including ground-glass opacities and consolidation, typically reversible upon drug cessation. Bronchoalveolar lavage findings in confirmed cases show lymphocytic alveolitis, suggesting an immune-mediated rather than direct toxic mechanism.

Clinically, SAP typically presents 6 weeks to 6 months after sirolimus initiation, with dry cough, dyspnea, and low-grade fever. CT imaging shows bilateral infiltrates. The FDA label recommends discontinuation in patients with confirmed SAP, noting that cases have been fatal when not recognized promptly. PubMed-indexed case literature dating to 2004 documents fatal outcomes when pneumonitis was attributed to infection rather than sirolimus and treated with escalating immunosuppression.

Hyperlipidemia and Cardiovascular Risk

The FDA label for Rapamune notes that in the key phase III trials (Study 1 and Study 2, N=576 and N=477 respectively), hypercholesterolemia occurred in 38 to 43% of sirolimus-treated patients versus 21 to 23% of azathioprine controls. Hypertriglyceridemia was reported in 38 to 53% of sirolimus patients. These rates are dose-dependent; the 2 mg/day arm consistently showed lower lipid elevations than the 5 mg/day arm in Study 2 data.

For the longevity patient population, the cardiovascular risk implication differs from transplant patients because longevity protocols use intermittent dosing. A 2019 pharmacokinetic study in Aging Cell found that weekly sirolimus dosing produced peak trough levels of 2.3 to 5.7 ng/mL at steady state, compared to daily dosing troughs of 8 to 15 ng/mL in transplant maintenance, suggesting substantially lower lipid-pathway mTORC1 suppression between doses.

Infection Risk and Opportunistic Pathogens

The black-box warning for increased infection susceptibility reflects a consistent FAERS signal. Among opportunistic infections, Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV), and BK virus nephropathy appear most frequently in transplant-context reports. The FDA Drug Safety Communication from 2009 addressed serious skin reactions, a lower-frequency but high-severity signal.

A 2021 retrospective cohort published in JASN found that sirolimus-treated renal transplant recipients had a 1.4-fold higher rate of bacterial infections in the first year compared to tacrolimus-treated controls, though the absolute rates were modest (22.3% vs. 15.9%, P<0.001).

Wound Healing and Surgical Considerations

The FDA label contains a specific recommendation to interrupt or discontinue sirolimus perioperatively due to documented wound-healing impairment. This signal is mechanistically coherent: mTORC1 inhibition reduces fibroblast proliferation, collagen synthesis, and angiogenesis, all of which are required for normal wound repair. A 2003 study in Surgery demonstrated reduced tensile strength in sirolimus-treated rat wound models at 10 and 21 days post-incision compared to controls (P<0.01).

For patients using low-dose sirolimus off-label, surgeons and prescribers should coordinate on an interruption protocol. No consensus guideline exists for off-label longevity use, but the transplant literature generally recommends stopping sirolimus at least 7 days before elective surgery given the approximately 62-hour half-life.

The PEARL Trial: Low-Dose Sirolimus and Immune Aging

The PEARL trial (Targeting Aging with Rapamycin for Longevity Extension) represents the most rigorous prospective data on low-dose sirolimus safety in older, non-transplant adults. Published in Aging Cell in 2024 (N=333, community-dwelling adults aged 50 and older), PEARL randomized participants to sirolimus 1 mg/day, 2 mg/day, 5 mg/day, or placebo for 12 weeks. PEARL full text via PubMed.

PEARL Safety Findings

At the 1 mg/day and 2 mg/day doses, the adverse event profile was largely indistinguishable from placebo. At 5 mg/day, the trial reported a statistically significant increase in oral ulcers (stomatitis; 18.6% vs. 3.1% placebo, P<0.01) and modest triglyceride elevation (mean increase of 28 mg/dL vs. 4 mg/dL placebo). No cases of clinical pneumonitis were observed at any dose over the 12-week period, though the trial duration was insufficient to capture the typical 6-week to 6-month onset window for SAP.

PEARL and FAERS Signal Relevance

The PEARL data do not contradict the FAERS signals; they provide dose and duration context. The pneumonitis signal identified in FAERS and the transplant literature predominately originates from daily dosing at 2 to 5 mg/day over months to years with troughs in the 4 to 12 ng/mL range. PEARL's short duration and lower daily exposures cannot rule out SAP risk at longevity protocol doses; they only suggest the acute (less than 12-week) risk is low at 1 to 2 mg/day. Longer prospective safety data at weekly 5 to 6 mg doses remain a gap in the published literature.

How Does the FDA Label Address Off-Label Longevity Use?

The current FDA-approved label for sirolimus does not address anti-aging or longevity applications. The label's dosing section covers renal transplant (loading dose 6 mg, then 2 mg/day maintenance in low-risk patients) and LAM (2 mg/day titrated to trough 5 to 15 ng/mL). There is no labeled dose for immune rejuvenation or mTOR-pathway modulation for aging. Prescribers operating outside those indications bear full responsibility for informed consent and monitoring.

What the Label Requires for Monitoring

For approved indications, the label mandates:

• Sirolimus trough level monitoring via whole-blood chromatographic assay, targeting 4 to 12 ng/mL in the maintenance phase.
• Lipid panel at baseline and after 4 to 8 weeks of therapy, with statin or fibrate treatment if needed.
• Complete blood count (CBC) to monitor for thrombocytopenia and anemia.
• Renal function monitoring, particularly if sirolimus is co-administered with calcineurin inhibitors.
• Chest X-ray or CT if respiratory symptoms develop.

Off-label longevity protocols published in peer-reviewed case series (such as Mannick et al., Science Translational Medicine 2014, N=218, using RAD001/everolimus as a surrogate) typically adopt a modified version of this monitoring framework with less frequent trough sampling given the different pharmacokinetic profile of weekly dosing.

Drug Interactions Flagged by the Label

Sirolimus is a CYP3A4 and P-glycoprotein substrate. The label lists co-administration with strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, diltiazem) as capable of increasing sirolimus AUC by 4- to 11-fold. Strong inducers (rifampin, rifabutin) reduce AUC by up to 82%. Grapefruit juice is specifically contraindicated. The FDA drug interaction guidance for sirolimus includes a comprehensive interaction table in Section 7 of the current label.

EMA and International Pharmacovigilance Data

The European Medicines Agency granted marketing authorization for Rapamune in 2001. The EMA EPAR for Rapamune includes periodic safety update reports (PSURs) summarizing post-market EU data. EU signals largely mirror FAERS findings: pneumonitis, hyperlipidemia, impaired wound healing, and opportunistic infections are the four principal ongoing signal categories. The EMA's pharmacovigilance risk assessment committee (PRAC) has issued label updates for sirolimus-class drugs on two occasions since 2010, both relating to hepatotoxicity and fluid accumulation signals in off-label indications.

A 2019 disproportionality analysis in the WHO VigiBase database covering 44,000 sirolimus case reports found that peripheral edema, pleural effusion, and lymphedema formed a distinct signal cluster beyond what the US label had historically emphasized. The information criterion (IC) for peripheral edema was 2.14 (IC025 1.87), which meets the threshold for a confirmed disproportionality signal in VigiBase methodology.

Post-Market Commitments and FDA Ongoing Surveillance

As a condition of approvals, Pfizer has completed several post-marketing studies for sirolimus, including a pediatric safety study under the Pediatric Research Equity Act. The FDA requires Pfizer to continue routine pharmacovigilance reporting under 21 CFR 314.81, including 15-day expedited reports for serious unexpected adverse drug reactions and annual reports summarizing all domestic and foreign case receipts.

The FDA Sentinel System adds a layer of active surveillance using claims data. Sentinel queries for mTOR inhibitors have been used to monitor the pneumonitis and malignancy signals. The Sentinel Common Data Model enables FDA to query without accessing individual patient records, generating population-level safety estimates. No public Sentinel module specifically addressing sirolimus longevity use had been released as of January 2025, reflecting the recency of widespread off-label prescribing in this context.

Clinical Bottom Line for Prescribers

Prescribers using sirolimus off-label for longevity indications should treat the FAERS signal list as a monitoring checklist, not a contraindication list. The five signals requiring active baseline and follow-up assessment are: pulmonary symptoms (SAP), lipid levels (hyperlipidemia), CBC (thrombocytopenia), oral mucosa inspection (stomatitis), and surgical timing (wound healing). At weekly doses of 1 to 6 mg producing troughs below 8 ng/mL, the absolute event rates from available data appear lower than daily transplant-dose exposures, but prospective long-term safety data remain limited to the 12-week PEARL window at this writing. Obtain a baseline lipid panel, CBC, and comprehensive metabolic panel before initiating sirolimus, recheck at 4 to 8 weeks, and repeat every 6 months thereafter per the monitoring framework adapted from the FDA-approved label.